Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer

NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its board of directors has appointed John H. Johnson as interim chief executive officer (CEO), effective immediately. Mr. Johnson, a director of Melinta, succeeds Dan Wechsler, who is stepping down from his role as president, CEO and director to pursue other opportunities. The Board and Mr. Wechsler mutually agreed that now is the right time to transition leadership of the Company.